A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Zhao, Shilin, Wang, Jing, Sheng, Quanhu, Liu, Qi, Shyr, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Resource Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189237/
https://www.ncbi.nlm.nih.gov/pubmed/34903605
http://dx.doi.org/10.1158/0008-5472.CAN-21-2335
Descripción
Sumario:The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a comprehensive platform that integrates large-scale multidimensional omics data, including genetic, bulk, and single-cell transcriptomic, proteomic, and dynamic genomic profiles, with clinical phenotypes to explore consistent and rare immunogenomic connections. Currently Cancer-Immu has incorporated data for 3,652 samples for 16 cancer types. It provides easy access to immunogenomic data and empowers researchers to translate omics datasets into biological insights and clinical applications. SIGNIFICANCE: Cancer-Immu is a comprehensive functional portal for unraveling immune-genomic connections to improve immune checkpoint blockade–based cancer immunotherapy.

Ejemplares similares